Lowering the High Cost of Cancer Drugs--II.
نویسندگان
چکیده
EU Government brings cost of hepatitis C drug to V5,000 below list price, published 21st November 2014, PMLIVE website. http://www. pmlive.com/pharma_news/france_agrees_lowest_ sovaldi_pricing_in_eu_618661. Accessed January 22, 2016. 9. Messori A. Spend less on drug enforcement and more on treating hepatitis C, say campaigners [response]. BMJ website. http://www.bmj.com/ content/346/bmj.f3428/rr/689912. Published March 11, 2014. Accessed November 1, 2014. 10. Shrank W, Lotvin A, Singh S, Brennan T. In the debate about cost and efficacy, PCSK9 inhibitors may be the biggest challenge yet. Health Affairs Blog. http://healthaffairs.org/blog/2015/ 02/17/in-the-debate-about-cost-and-efficacy-pcsk9inhibitors-may-be-the-biggest-challenge-yet/. Published February 17, 2015. Accessed July 20, 2015.
منابع مشابه
Cost evaluation of chemotherapy and epidemiology of five most common cancers in Isfahan Province in Iran
Background: Cancer is the third leading cause of death in Iran. Cancer treatment is very costly and chemotherapy drugs are one of the main causes of the high cost of cancer treatment. The purpose of this study was to evaluate the cost of chemotherapy drugs of five most common cancers and identifying the factors might affect the costs of chemotherapy drugs in a one of the large provinces of Iran...
متن کاملAttitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs
Background Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some e...
متن کاملDespite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...
متن کاملDespite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...
متن کاملSynthesis of Cis-Diammine (1,1-cyclobutane dicarboxylate) Platinum(II)
Platinum-based anticancer drugs are chemotherapeutic agents to treat cancer. Carboplatin (cis diammine cyclobutane dicarboxylate platinum (II)) is a second generation drug that has less toxic than cisplatin, allowing for high dosages. In the first stage, 1,3-Cyclobutane dicarboxylic acid, a key intermediate for the preparation of carboplatin, have been synthesized in good yields using diffe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Mayo Clinic proceedings
دوره 91 3 شماره
صفحات -
تاریخ انتشار 2016